Cutaneous T-cell lymphoma at all stages appears to be responsive to immune modulatory therapeutic approaches. of immune modulatory therapy remains an important treatment approach leading to significant clinical benefit, even for those with advanced CTCL. Moreover, those with early stage disease are particularly responsive to immune modulatory therapy. In choosing the ideal immune modulator, a… Continue reading Cutaneous T-cell lymphoma at all stages appears to be responsive to